Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec Biopharma Ltd has Hepatitis B success with treatment

Benitec Biopharma Ltd has Hepatitis B success with treatment

Benitec Biopharma Ltd (ASX:BLT; NASDAQ:BNTC) should gain a boost today as its Hepatitis B therapy has been seen to reduce the virus (HBV) by 98.5% in a mice study.

The in vivo study assessed the activity of BB-HB-331 treatment in the PhoenixBio (PXB) mouse model and demonstrated robust and durable suppression of HBV in vivo following a single administration.

Benitec's ddRNAi technology is a combination of gene silencing using RNA interference coupled with the long term therapeutic potential of gene therapy.

Once infected with HBV, mice were treated with a one time systemic injection of BB-HB-331. Weekly assessment of serum antigen levels, HBV viral proteins and extracellular HBV DNA were conducted for the duration of the 56 day study.

The key findings in this study were that a single BB-HB-331 treatment reduced serum HBV DNA by 1.83 logs, equivalent to 98.5% elimination of circulating HBV.

The in vivo experiment validates the BB-‐HB-331 in vitro findings previously observed in human hepatocytes isolated from the PXB mouse model which was announced on 7 December 2015.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

 

 

 



Register here to be notified of future BLT Company articles
View full BLT profile

Benitec Ltd. Timeline

Newswire
August 18 2015
Newswire
November 11 2014
Newswire
February 24 2014

Related Articles

shutterstock_234586750.jpg
Thu
N+1, in a note to clients, described the financial performance as “solid”, which perhaps understated Abzena’s progress in the six months to September 30.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Blood test
September 28 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.